Response to Yang, Shi, Wang et al
J Natl Cancer Inst
.
2020 Apr 1;112(4):428.
doi: 10.1093/jnci/djz163.
Authors
Mok Oh
1
,
Ali McBride
2
3
,
Seongseok Yun
4
,
Sandipan Bhattacharjee
5
,
Marion Slack
5
,
Jennifer R Martin
6
5
,
Joanne Jeter
7
,
Ivo Abraham
1
5
2
8
Affiliations
1
Center for Health Outcomes and PharmacoEconomic Research, Tucson, AZ.
2
University of Arizona Cancer Center, Tucson, AZ.
3
University of Arizona, Tucson, AZ; Banner University Medical Center, University of Arizona Cancer Center, Tucson, AZ.
4
H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL.
5
Department of Pharmacy Practice and Science, Tucson, AZ.
6
Arizona Health Sciences Library, Tucson, AZ.
7
Departments of Human Genetics and Medical Oncology, College of Medicine, The Ohio State University, Columbus, OH.
8
College of Pharmacy, and Department of Family and Community Medicine, College of Medicine-Tucson, Tucson, AZ.
PMID:
31424546
PMCID:
PMC7156932
DOI:
10.1093/jnci/djz163
No abstract available
Publication types
Letter
Comment
MeSH terms
BRCA1 Protein
BRCA2 Protein
Colonic Neoplasms*
Colorectal Neoplasms*
Genes, BRCA2
Humans
Mutation
Substances
BRCA1 Protein
BRCA1 protein, human
BRCA2 Protein
BRCA2 protein, human